Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- (Update) 3 Pharma Groups Push for Price Maintenance during Patent Term: Chuikyo Hearing
May 18, 2017
- MHLW Study Group to Issue Report Calling for Guidelines to Promote Efficient Development of Biosimilars
May 18, 2017
- Japan Drug Market Could Shrink Annual 1.5% by FY2026: EFPIA Simulation
May 17, 2017
- Continue Price Maintenance Scheme without Shedding Eligible Products: PhRMA
May 17, 2017
- 3 Pharma Groups Push for Price Maintenance during Patent Term: Chuikyo Hearing
May 17, 2017
- Ninlaro, 7 Other Drugs OK’ed for Reimbursement Listing on May 24
May 17, 2017
- Japan, South Korea Set Up Working Groups to Collaborate on Harmonization
May 16, 2017
- Procedures for Providing Unapproved Drugs to Developing Countries in Emergencies Could Become Finalized in June
May 15, 2017
- Transition Period of “at Least 1 Year” Needed for New Package Insert Format: MHLW
May 11, 2017
- Marketing Strategies for Participating Hospitals to Be Important for Drug Makers to Effectively Use MID-NET: PMDA Official
May 11, 2017
- LDP Confab Sees Japan Execs’ Chorus for Drug Price Maintenance during Patent Term
May 10, 2017
- Japan, US Ink Memorandum of Cooperation on Health
May 9, 2017
- Health Minister Shiozaki Stresses Importance of US-Japan Alliance in Healthcare
May 9, 2017
- Japan and India to Share Common View on Global Clinical Trials
May 9, 2017
- “Specified Clinical Research” Data with High Integrity Could Be Used for Drug Review: MHLW Councilor
May 8, 2017
- Experts Support Revision of Rules to Promote Concurrent Administration of Multiple Vaccines: MHLW Vaccine Panel
May 8, 2017
- MHLW Study Group Drafts “Items to Consider” to Promote Development of Nucleic Acid Drugs
May 2, 2017
- MHLW Poised to Create Standards for Cancer Treatment in the Elderly
May 1, 2017
- 2017 Economic and Fiscal Policy Guidelines Likely to Be Tinged with MOF Color
April 28, 2017
- MHLW to Draw Up Guidelines on Use of MID-NET in Summer
April 28, 2017
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…